JP2006528650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528650A5 JP2006528650A5 JP2006521498A JP2006521498A JP2006528650A5 JP 2006528650 A5 JP2006528650 A5 JP 2006528650A5 JP 2006521498 A JP2006521498 A JP 2006521498A JP 2006521498 A JP2006521498 A JP 2006521498A JP 2006528650 A5 JP2006528650 A5 JP 2006528650A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- amino acid
- peptide
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 36
- 230000002163 immunogen Effects 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 239000000562 conjugate Substances 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 235000018102 proteins Nutrition 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000002502 liposome Substances 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 230000006698 induction Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- PCLFEHAPITXKJL-UHFFFAOYSA-N 5,8-dihydroxy-2-[2-(4-methoxyphenyl)ethyl]chromen-4-one Chemical compound C1=CC(OC)=CC=C1CCC1=CC(=O)C2=C(O)C=CC(O)=C2O1 PCLFEHAPITXKJL-UHFFFAOYSA-N 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229940037003 alum Drugs 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 108091005601 modified peptides Proteins 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 1
- 241000588921 Enterobacteriaceae Species 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 101150066553 MDR1 gene Proteins 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000011325 microbead Substances 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000863 peptide conjugate Substances 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical group 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000000277 virosome Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0309188A FR2857875A1 (fr) | 2003-07-25 | 2003-07-25 | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
| PCT/EP2004/008330 WO2005014036A1 (fr) | 2003-07-25 | 2004-07-25 | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013018233A Division JP2013121977A (ja) | 2003-07-25 | 2013-02-01 | 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528650A JP2006528650A (ja) | 2006-12-21 |
| JP2006528650A5 true JP2006528650A5 (enExample) | 2007-08-30 |
Family
ID=33561147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521498A Pending JP2006528650A (ja) | 2003-07-25 | 2004-07-25 | 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン |
| JP2013018233A Withdrawn JP2013121977A (ja) | 2003-07-25 | 2013-02-01 | 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013018233A Withdrawn JP2013121977A (ja) | 2003-07-25 | 2013-02-01 | 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060233758A1 (enExample) |
| EP (2) | EP2316478B1 (enExample) |
| JP (2) | JP2006528650A (enExample) |
| KR (2) | KR20060125676A (enExample) |
| CN (1) | CN1856323B (enExample) |
| AU (1) | AU2004262472B2 (enExample) |
| CA (1) | CA2533540C (enExample) |
| FR (1) | FR2857875A1 (enExample) |
| WO (1) | WO2005014036A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US7807171B2 (en) * | 2003-07-25 | 2010-10-05 | Ac Immune Sa | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| US20080026995A1 (en) * | 2003-07-25 | 2008-01-31 | Ac Immune Sa | Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| US8090392B2 (en) * | 2005-08-05 | 2012-01-03 | Interdigital Technology Corporation | Method and system for reporting a short message capability via an IP multimedia subsystem |
| PT2484375T (pt) | 2006-09-26 | 2018-07-09 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| KR101130754B1 (ko) * | 2010-06-25 | 2012-03-28 | 제일약품주식회사 | 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물 |
| EP2603233A1 (en) | 2010-08-12 | 2013-06-19 | AC Immune S.A. | Vaccine engineering |
| TW201223561A (en) | 2010-10-26 | 2012-06-16 | Ac Immune Sa | Preparation of an antigenic construct |
| US9555099B2 (en) | 2012-05-16 | 2017-01-31 | Immune Design Corp. | Vaccines for HSV-2 |
| AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
| CN113508127A (zh) | 2018-11-06 | 2021-10-15 | 阿尔萨泰克公司 | 神经变性疾病的基于细胞的基因疗法 |
| CN112767998B (zh) * | 2019-01-29 | 2024-10-08 | 杭州纽安津生物科技有限公司 | 针对靶向药物达拉菲尼、派姆单抗、威罗菲尼、司美替尼的多肽疫苗组合及其设计方法 |
| CN113648429B (zh) * | 2021-07-06 | 2023-11-10 | 中山大学 | 靶向肿瘤周围细胞激活免疫的聚合物及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1257893B (it) * | 1992-06-17 | 1996-02-16 | Ist Superiore Sanita | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana. |
| WO1994010198A1 (en) * | 1992-11-02 | 1994-05-11 | Yves Claude Nicolau | Method of reducing multidrug resistance in cells and tissues |
| JP3759759B2 (ja) * | 1994-03-04 | 2006-03-29 | 日本油脂株式会社 | リポソームおよび薬物運搬体 |
| JP4385152B2 (ja) * | 1997-09-17 | 2009-12-16 | 三菱化学株式会社 | ２価反応性水溶性高分子誘導体及びそれを含有する複合体 |
| JP2002047298A (ja) * | 2000-07-10 | 2002-02-12 | Academia Sinica | 新規抗がん剤伝達系 |
| US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| NZ543934A (en) * | 2003-05-12 | 2008-06-30 | Affymax Inc | Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds |
-
2003
- 2003-07-25 FR FR0309188A patent/FR2857875A1/fr not_active Withdrawn
-
2004
- 2004-07-25 KR KR1020067001783A patent/KR20060125676A/ko not_active Ceased
- 2004-07-25 WO PCT/EP2004/008330 patent/WO2005014036A1/fr not_active Ceased
- 2004-07-25 EP EP10185331.5A patent/EP2316478B1/fr not_active Expired - Lifetime
- 2004-07-25 CN CN2004800274241A patent/CN1856323B/zh not_active Expired - Fee Related
- 2004-07-25 AU AU2004262472A patent/AU2004262472B2/en not_active Ceased
- 2004-07-25 EP EP04763487.8A patent/EP1651257B1/fr not_active Expired - Lifetime
- 2004-07-25 CA CA2533540A patent/CA2533540C/fr not_active Expired - Fee Related
- 2004-07-25 KR KR1020127033292A patent/KR20130008092A/ko not_active Ceased
- 2004-07-25 JP JP2006521498A patent/JP2006528650A/ja active Pending
-
2005
- 2005-11-16 US US11/274,885 patent/US20060233758A1/en not_active Abandoned
-
2013
- 2013-02-01 JP JP2013018233A patent/JP2013121977A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528650A5 (enExample) | ||
| KR101208173B1 (ko) | 초분자 구조체를 포함하는 방법 및 조성물 | |
| ES2551604T3 (es) | Vacuna terapéutica | |
| Pöltl-Frank et al. | Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine | |
| JP2013121977A5 (enExample) | ||
| JP2009510133A5 (enExample) | ||
| US8409580B2 (en) | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers | |
| JP5519477B2 (ja) | Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン | |
| JP2013121977A (ja) | 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン | |
| JP2014503475A5 (enExample) | ||
| JP2014518841A (ja) | アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン | |
| CN111499753A (zh) | 双功能抗体及其用途 | |
| US12280109B2 (en) | Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines | |
| Wallis et al. | A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response | |
| US7314956B2 (en) | Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell | |
| JP2001510440A (ja) | ムチン接合体ペプチドワクチン | |
| JP2008545759A (ja) | コレステリルエステル転送タンパク質（ｃｅｔｐ）活性の調節 | |
| US20080175871A1 (en) | Eliciting improved immune responses | |
| WO2019120063A1 (zh) | 低pH插入肽及其组合物 | |
| CN1446094A (zh) | 获得可增强特异交叉反应性的抗原结构的方法 | |
| US20050255561A1 (en) | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers | |
| JPWO2022060488A5 (enExample) | ||
| ES2385226T3 (es) | Métodos y composiciones que comprenden construcciones supramoleculares | |
| Luna González | Peptides: from synthesis to biomedical application in two types of cancer | |
| González | Peptides: From Synthesis to Biomedical Application in Two Types of Cancer |